Nucleostim-VEGF

Nucleostim-VEGF is a first-in-class gene-activated bone substitute developed by Histograft Co., Ltd. for the treatment of maxillofacial bone defects and alveolar ridge atrophy. The product consists of an octacalcium phosphate (OCP) scaffold combined with plasmid DNA encoding vascular endothelial growth factor (VEGF-A, specifically the VEGF165 isoform). Upon surgical implantation into a bone defect, local cells internalize the plasmid DNA and begin producing VEGF-A protein. This localized expression of VEGF stimulates angiogenesis and promotes the recruitment and differentiation of osteogenic cells, thereby accelerating bone tissue regeneration. Nucleostim-VEGF received marketing authorization in Russia in 2019 following successful Phase III clinical trials, representing a novel intersection of medical devices and gene therapy.

Brand names

Nucleostim-VEGF

Other names

Nucleostim VEGFGistograftHistograft